ArfGAP with GTPase domain, ankyrin repeat and PH domain 9Genealiases: AGAP-9 · CTGLF6 · bA301J7.2
Q-omics provides the consensus-scored AGAP9 profile across patient tissues and cancer cell-line models. AGAP9 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AGAP9 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, AGAP9 RNA expression shows 17,160 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where AGAP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AGAP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AGAP9 survival associations across molecular data types. AGAP9 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AGAP9 RNA expression–survival associations across cancer types. High AGAP9 expression shows unfavorable associations in KIRC, COAD and ACC, but favorable associations in BLCA, HNSC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AGAP9 RNA expression.
This table summarizes AGAP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for AGAP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AGAP9 shows lower tumor expression in KICH, BRCA and THCA and higher tumor expression in READ, COAD and LIHC. The KICH box plot shows higher AGAP9 RNA expression in normal versus tumor tissue (log2 FC = −1.070, t-test p < 0.001).
This table shows molecular features associated with AGAP9 in patient tissues and cancer cell lines. In patient samples, AGAP9 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, AGAP9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and SOFT_TISSUE.
